Skip to content

Daclatasvir Impurity 9

Daclatasvir Impurity 9

Product Description
CAT No.
ALN-D036031
CAS No.
1447744-93-5
Mol. F.
C30H32N6O2
Mol. Wt.
508.6
Stock
Please Inquire
Chemical Name : 1,1′-(2S,2’S)-2,2′-(5,5′-([1,1′-Biphenyl]-4,4′-diyl)bis[1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))diethanone
Smiles : O=C(C)N1CCC[C@H]1C2=NC=C(N2)C3=CC=C(C4=CC=C(C5=CN=C([C@@H]6CCCN6C(C)=O)N5)C=C4)C=C3
Inchi : InChI=1S/C17H28N5O7P/c1-11(2)28-17(23)25-9-27-30(24,29-12(3)4)10-26-13(5)6-22-8-21-14-15(18)19-7-20-16(14)22/h7-8,11-13H,6,9-10H2,1-5H3,(H2,18,19,20)/t13-,30?/m1/s1

A validated stability-indicating reverse-phase high-performance liquid chromatography method for daclatasvir, identification and characterization of degradation products using LC-ESI-QTOF-MS

By Warghade, Snehal V.; Bothara, Kailash G.nFrom Asian Journal of Pharmaceutical and Clinical Research (2019), 12(5), 302-308

Development and validation of HPLC fluorescence and UPLC/DAD stability-indicating methods for determination of hepatitis C antiviral agent daclatasvir

By Kamal, Andra H.; Ismail, Nahla S.; Mabroijk, Mokhtar M.; Bebawy, Lories I.; Mekky, Mai A. – From Journal of AOAC International (2019), 102(4), 1125-1131

A stability-indicating UPLC method for the determination of potential impurities and its mass by a new QDa mass detector in daclatasvir drug used to treat hepatitis C infection

By Jagadabi, Varaprasad; Kumar, P. V. Nagendra; Mahesh, Kasthuri; Pamidi, Srinivasu; Ramaprasad, L. A.; Nagaraju, D. – From Journal of Chromatographic Science (2019), 57(1), 44-53

Request For Quotation